Morphosys AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Morphosys AG Reaffirms FY 2013 Guidance-Conference Call
Morphosys AG announced that for fiscal 2013, it expects total group revenues between EUR68 million to EUR72 million and an EBIT of between EUR(2) million and EUR2 million. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of EUR69 million for fiscal 2013.
Latest Developments for Morphosys AG
Latest Key Developments in Biotechnology
- Tekmira Pharmaceuticals Corp announces proposed public offering of common stock
- La Jolla Pharmaceutical Co reports positive, top-line results from phase 2 clinical trial of gcs-100 in chronic kidney disease
- FDA designates Regado Biosciences Inc's REG1 in PCI as a fast track development program
- Omeros Corporation announces positive OMS721 Data in Serum from patients with aHUS
- Share this
- Digg this